试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-09-24
Pharmacokinetics, Pharmacodynamics And Safety Study Of Elelyso(tm) In Pediatric Subjects With Type 1 Gaucher Disease
编号:NCT03021941登记状态:入组前撤回企业 / 申办者:Pfizer
药物 / 成分:Elelyso 60 units/kg
登记的停止原因(原文):In a communication dated June 12, 2019 the FDA has released Pfizer from the Postmarketing Commitment (PMC 2767-2) that was associated with study B3031003.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-09-23
HyGIeaCare Prep vs Split-dose PEG Prep Prior to Colonoscopy
编号:NCT02893748登记状态:入组前撤回企业 / 申办者:HyGIeaCare, Inc.
药物 / 成分:HyGIeaCare Prep、Colonoscopy、polyethylene glycol (PEG)
登记的停止原因(原文):unable to agree on budget terms
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-09-23
Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects
编号:NCT03315052登记状态:入组前撤回企业 / 申办者:Montefiore Medical Center
药物 / 成分:Budesonide、Tacrolimus(FK506)、Mycophenolate Mofetil、Prednisone
登记的停止原因(原文):Delay in IRB approval
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-09-19
Mifepristone Versus Osmotic Dilators in Conjunction With Misoprostol for Cervical Preparation Prior to D&E at 14-19 Weeks
编号:NCT02679092登记状态:入组前撤回企业 / 申办者:Stanford University
药物 / 成分:Misoprostol、Mifepristone、Hygroscopic cervical dilators
登记的停止原因(原文):Funding changes.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-09-19
A Randomized Trial of Rosuvastatin Loading Combined With Early hydrAtion Versus Standard-of-care Medications for the Prevention of CIAKI in Patient With AMI Undergoing Emergency PCI
编号:NCT03526367登记状态:入组前撤回企业 / 申办者:Shenyang Northern Hospital
药物 / 成分:hydration plus rosuvastatin therapy、Standard therapy
登记的停止原因(原文):Study withdrawn for no sufficient fund support.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-09-19
Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20
编号:NCT03605238登记状态:入组前撤回企业 / 申办者:Chinese PLA General Hospital
药物 / 成分:Corticosteroids & tanCART19/20
登记的停止原因(原文):It was hard to recruit patients
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-09-19
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
编号:NCT03766607登记状态:入组前撤回企业 / 申办者:Korean South West Oncology Group
药物 / 成分:Trastuzumab、Ramucirumab、Paclitaxel
登记的停止原因(原文):Competing other studies
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-09-19
Alcohol Withdrawal Syndrome Treated With Adjunctive Phenobarbital or Ketamine
编号:NCT03788889登记状态:入组前撤回企业 / 申办者:Santa Barbara Cottage Hospital
药物 / 成分:Ketamine、Phenobarbital、Lorazepam、Placebo A
登记的停止原因(原文):internal practice and policy limitations including time commitment / workflow issues
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-09-18
RCVS: The Rational Approach to Diagnosis and Treatment
编号:NCT03150524登记状态:入组前撤回企业 / 申办者:Johns Hopkins University
药物 / 成分:TCD- cerebral blood flow velocities、Headache pain score、Neurological examination、Repeat Neuroimaging
登记的停止原因(原文):Failure to recruit patients meeting inclusion criteria.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-09-18
The Correlation of Surgical Colorectal Cancer Specimen Pathology With the Fluorescence of Photodynamic Diagnostics
编号:NCT03272659登记状态:入组前撤回企业 / 申办者:Dr. Te Vuong
药物 / 成分:Cysview
登记的停止原因(原文):Long process and due to strict deadline, project was stopped.
查看官方原始记录 ↗